Jacqueline C. Barrientos, MD, MS

home / authors / jacqueline-c-barrientos-md-ms

Articles

Expert on CLL

Optimizing the Treatment of CLL With Novel Therapies

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO
March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

Read More

Experts on CLL

CAR T-Cell Therapies in CLL

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO
March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Read More

Jacqueline Claudia Barrientos, MD, MS, of Northwell Health

Dr. Barrientos on the Shift Away From Chemoimmunotherapy in CLL

Jacqueline C. Barrientos, MD, MS
April 19th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Read More

Dr. Barrientos on Remaining Challenges in CLL

Dr. Barrientos on Remaining Challenges in CLL

Jacqueline C. Barrientos, MD, MS
May 24th 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses remaining challenges in the treatment of patients with chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data